CONFERENCE SERIES: Chemistry
Recorded at: Discovery on Target
Digital Course: Best Practices for Setting Up Effective RNAi Screens
About this Product:
This digital course brings you the recording of the course on “Best Practices for Setting up Effective RNAi Screens” that took place on November 3, 2010. The course goes into details on how to design, set-up and run RNAi screens for various applications. The instructors provide information on how the screens are functioning in their facilities and offer advice on what has worked and not worked for them. The course is a valuable resource for scientists looking to design both low and high-throughput RNAi screens on a routine basis.
About this Product:
Over 178 Slides
Individual Copy: $345
Site License: $1380
Agenda at a Glance:
The course is designed to provide in-depth information on how to go about setting up RNAi screening experiments and how to design assays for getting optimal results. The challenges working with siRNAs and shRNAs and the delivery reagents needed to get them into the appropriate cells and tissues will be discussed. The instructors will also provide their input on best practices for the execution of experiments and interpretation of results when dealing with complex biology and informatics.
Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan Kettering Cancer Center
Biography: Dr. Hakim Djaballah has several years of industrial experience in preclinical drug discovery gained over the years in pharma and biotech companies. He has been involved in developing and screening targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He was recruited to MSKCC in 2003 to set up and direct the HTS Core Facility, a drug discovery laboratory involved in both chemical and functional genomics screening. The HTS laboratory became fully functional in August, 2004. Today the Center’s chemical library consists of nearly 380,000 compounds and their proprietary small interfering RNA libraries consists of nearly 21,000 duplexes covering 6000 genes. Their collection also includes libraries licensed from other commercial sources. The facility has now developed and validated nearly 56 assays and these screens have led to the identification of several “hits”, initiated exploratory chemistry around several scaffolds and have led to patent filings and progression of compounds into the clinic. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and completed his PhD in biochemistry from the University of Leicester, both in England.
Serena Silver, Ph.D., RNAi Screening Projects Group Leader, Broad Institute at MIT
Biography: Dr. Serena Silver is the RNAi Screening Projects Group Leader for the RNAi Platform at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University. Her lab is a part of The RNAi Consortium (TRC), which is a public-private consortium based at the Broad Institute, looking to develop RNAi reagents and technologies for functional analysis. The first phase of TRC’s efforts involved the creation of an RNAi library consisting of 160,000 short hairpin RNA (shRNA) constructs targeting 15,000 human and mouse genes. The second phase launched in 2007 focuses on functional validation and making improvements to the library design. Silver received her Ph.D. in Biology from MIT, using the retinal determination network to study crosstalk amongst signaling pathways. While a post-doctoral fellow in Dr. Norbert Perrimon’s lab at Harvard Medical School, she was introduced to laboratory automation and the large datasets that result from RNAi screening at the Drosophila RNAi Screening Center, and continued to study gene networks, examining the role of micro RNAs (miRNAs) in signal transduction pathways. Presently the Group Leader for Screening in the RNAi Platform at the Broad Institute, she collaborates with dozens of labs on RNAi screening projects, using the lentiviral shRNA library in arrayed and pooled formats.
Marc Ferrer, Ph.D., Team Leader, NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health
Biography: Dr. Marc Ferrer got his BSc in Organic Chemistry from the University of Barcelona, Spain, in 1989. In 1994, he completed his Ph.D. in Biological Chemistry from the University of Minnesota, Minneapolis, working on new methodologies for peptide synthesis and studying the molecular basis for protein folding. He then moved to the Department of Molecular and Cell Biology at Harvard University, Cambridge, as a postdoctoral fellow, where he used combinatorial chemistry and phage display methodologies to identify peptides and peptidomimetics that blocked HIV infection. In 1999, he joined the Department of Automated Biotechnology, the Central HTS group at Merck Research Laboratories, developing assays and implementing high throughput screens for lead and target identification. For the last ten years, he developed extensive expertise in assay development and miniaturization to implement small molecule high throughput screening in 1536- and 3456-well formats for lead identification. He also implemented siRNA HTS for target identification, developing new automation-friendly siRNA transfection protocols, improved data analysis tools for hit selection and strategies for better on-target hit validation. He also used large scale chemical genomics approaches for more efficient target and lead identification and pathway mapping in physiologically relevant cellular systems, combining assays with multiplexed readouts with compound/RNAi libraries. Recently, he joined the NIH Chemical Genomics Center where he is a Team Leader in the Biomolecular Profiling and Screening group, and where he continues to develop and implement chemical genomics approaches using small molecule and siRNA screens to identify tools to functionally probe biological systems and develop new therapeutics for rare and neglected diseases.
About the Conference:
Discovery on Target is CHI’s premier Drug Discovery event that brings to light the latest developments in the science and technologies underlying cellular pathways and drug targets. In its eighth year of production Discovery on Target, covers a diverse set of topics and captures an international audience spanning both industry and academia.